Unable to produce energy, photoreceptors trigger age-related macular degeneration.
Sylentis reports positive Phase II results with SYL1001 in treating ocular pain
Sylentis, a pharmaceutical company in the PharmaMar Group (MSE:PHM) and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has presented the…
Uncategorized
Micro-stent combined with phaco reduces IOP, medication use at 3 years
FORT LAUDERDALE, Fla. — A supraciliary micro-stent reduced IOP with a high safety profile in patients with open-angle glaucoma, according to a scientific poster presented at the American Glaucoma Society meeting here. Reay H. Brown, MD, and colleagues reported results of the CyPass Clinical Experience study, a prospective, multicenter analysis that included 522 patients; 269 patients underwent combined small-incision cataract surgery and implantation of a CyPass micro-stent (Transcend Medical). Of the 269 patients who had combined surgery, 102 had uncontrolled IOP (21 mm Hg or higher) and 167 had controlled IOP (lower than 21 mm Hg).
Fish and insects guide design for future contact lenses
NIH-funded researchers seek alternative to current options for a common eye disorder.
Uncategorized
Allegro Ophthalmics Announces Two Executive Promotions
SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)–Allegro Ophthalmics announces the promotion of Vicken Karageozian, MD, to President and Chief Medical Officer, and John Park, PhD, to Chief Scientific Officer and VP of Manufacturing Development.
Drugs to help energy-starved photoreceptors offers new avenue for treating AMD , MacTel
New research from Boston Children’s Hospital could potentially change how doctors approach two blinding diseases: ‘Wet’ age-related macular degeneration (AMD), the leading cause of blindness in the elderly, and macular telangiectasia (MacTel).